{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:02:35Z","timestamp":1789970555957,"version":"4.0.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Purpose<\/jats:title>\n To construct and preliminarily validate a novel nomogram for primary aldosteronism (PA) risk estimation, with the goal of providing a potential reference tool for PA screening in clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Hypertensive inpatients who underwent PA screening at the Department of Endocrinology and Metabolism, Cardiology, and Urology of Tianjin Medical University General Hospital from October 2021 to July 2024 were included. Basic information and laboratory test results of the patients were collected, and were randomly divided into training set and validation set at a 7:3 ratio. Differential analysis, Lasso regression, univariate logistic regression, and multivariate logistic regression were used to screen the variables associated with PA. The model results were presented as a nomogram. Predictive ability was assessed by plotting receiver operating characteristic (ROC) curves, and the diagnostic performance of the model was compared using the DeLong test. The Hosmer-Lemeshow test was used to evaluate the goodness of fit of the regression model. The clinical utility of the model was evaluated by clinical decision curve analysis (DCA).\n Kappa<\/jats:italic>\n test was used to evaluate the agreement between the model and ARR.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Six indicators including serum sodium-to-potassium ratio, anion gap, uric acid, urine sodium, 24-hour urine potassium and urine pH were used to construct a nomogram prediction model for PA. The training and validation sets achieved area under the curve (AUC) values of 0.860 (95% CI: 0.825\u20130.894) and 0.850 (95% CI: 0.800\u20130.899), respectively. The AUCs of the validation set for PFK score and ARR were 0.718 (95% CI: 0.656\u20130.781) and 0.965 (95% CI: 0.943\u20130.987), respectively. The model demonstrated good discrimination ability. The Hosmer-Lemeshow test indicated a good fit (training set:\n \u03c7\u00b2<\/jats:italic>\n =\u00a07.897,\n P<\/jats:italic>\n =\u00a00.444;validation set:\n \u03c7\u00b2<\/jats:italic>\n =\u00a06.208,\n P<\/jats:italic>\n =\u00a00.624). The DCA showed that the model had good clinical application value. The\n Kappa<\/jats:italic>\n test showed good agreement between the model and ARR(\n Kappa<\/jats:italic>\n =\u00a00.364,\n P<\/jats:italic>\n &lt;\u00a00.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The nomogram model based on serum sodium-to-potassium ratio, anion gap, uric acid, urine sodium, 24-hour urine potassium and urine pH can predict the risk of PA, facilitating PA screening in clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1875217","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:02Z","timestamp":1789968902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The nomogram prediction model for primary aldosteronism: the combination of serum and urine electrolytes and serum uric acid"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoyu","family":"Zha","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanv","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoliang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-44-1-1","article-title":"Primary aldosteronism, a new clinical entity","volume":"44","author":"Conn","year":"1956","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht534","article-title":"Secondary arterial hypertension: when, who, and how to screen","volume":"35","author":"Rimoldi","year":"2013","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121383-20201221-12058","article-title":"Investigation on current status of diagnosis of primary aldosteronism in China","volume":"42","author":"Yuan","year":"2022","journal-title":"Int J Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000001088","article-title":"Guidelines for primary aldosteronism: uptake by primary care physicians in Europe","volume":"34","author":"Mulatero","year":"2016","journal-title":"J Hypertens"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.05.085","article-title":"Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives","volume":"165","author":"Ruhle","year":"2019","journal-title":"Surgery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3760\/cma.j.cn311282-20241115-00546","article-title":"Expert consensus on the diagnosis and treatment of primary aldosteronism(2024)","volume":"41","year":"2025","journal-title":"Chin J Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.16386\/j.cjpccd.issn.1004-6194.2024.11.005","article-title":"The optimal cut-off point of plasma aldosterone\/renin ratio for screening primary aldosteronism among hypertensive population in Tianjin","volume":"32","author":"Yanv","year":"2024","journal-title":"Chin J Prev Control Chronic Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3969\/j.issn.1007-5410.2019.01.002","article-title":"2018 Chinese guidelines for the management of hypertensionwriting group of 2018","volume":"24","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000001511","article-title":"Screening of primary aldosteronism by clinical features and daily laboratory tests: combination of urine ph, sex, and serum k","volume":"36","author":"Yamashita","year":"2018","journal-title":"J Hypertens"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-022-06780-x","article-title":"Unilateral adrenalectomy for primary aldosteronism due to bilateral adrenal disease can result in resolution of hypokalemia and amelioration of hypertension","volume":"47","author":"Szabo Yamashita","year":"2023","journal-title":"World J Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad752","article-title":"Prolonged hypokalemia and delayed diagnosis of primary aldosteronism: clinical course and risk factors","volume":"109","author":"Gupta","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Sci (New York NY)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in Atp1a1 and Atp2b3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1295412","article-title":"Primary aldosteronism and metabolic syndrome","volume":"44","author":"Fallo","year":"2012","journal-title":"Horm Metab Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14873","article-title":"The prevalence of metabolic syndrome in primary aldosteronism and essential hypertension: a systematic review and meta-analysis","volume":"26","author":"Sun","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz293","article-title":"Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension","volume":"105","author":"Hu","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa177","article-title":"Diabetes mellitus itself increases cardio-cerebrovascular risk and renal complications in primary aldosteronism","volume":"105","author":"Saiki","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-023-01374-z","article-title":"A novel clinical-imaging nomogram for predicting primary aldosteronism in patients with hypertension","volume":"46","author":"Liu","year":"2023","journal-title":"Hypertens Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.12102\/j.issn.1672-1349.2020.02.031","article-title":"Comparison of glucose and lipid metabolism and uric acid levels between primary aldosteronism and essential hypertension","volume":"18","author":"Miaoyuan","year":"2020","journal-title":"Chin J Integr Med Cardio-Cerebrovascular Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.123.21474","article-title":"Primary aldosteronism in chronic kidney disease: blood pressure control and kidney and cardiovascular outcomes after surgical versus medical management","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14849","article-title":"Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease","volume":"98","author":"Nakano","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1507\/endocrine1927.68.1_51","article-title":"Study on uric acid metabolism in patients with primary aldosteronism","volume":"68","author":"Namba","year":"1992","journal-title":"Nihon Naibunpi Gakkai zasshi"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021113-170343","article-title":"The molecular physiology of uric acid homeostasis","volume":"77","author":"Mandal","year":"2015","journal-title":"Annu Rev Physiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1875217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:07Z","timestamp":1789968907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1875217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":30,"alternative-id":["10.3389\/fendo.2026.1875217"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1875217","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1875217"}}